Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Sulggi Lee, M.D., Ph.D. Assistant Professor of Medicine University of California,

Slides:



Advertisements
Similar presentations
Emerging patterns of drug resistance and viral tropism in cART-naïve and failing patients infected with HIV-1 subtype C Thumbi Ndung’u, BVM, PhD Associate.
Advertisements

New concepts in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference Nicolas Chomont VGTI-Florida.
Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway
Measuring the latent HIV Reservoir
The HDAC inhibitor romidepsin is safe and effectively reverses HIV-1 latency in vivo as measured by standard clinical assays Ole Schmeltz.
Unique integration patterns in an in vitro model of HIV-1 latency. Suha M. Saleh, Dimitrios Vatakis, Andrew Harman, Anthony Cunningham, Paul U. Cameron,
Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium.
Evaluating residual HIV reservoirs Background or why is this important? What can be measured? Where should we measure it? Conclusions.
Gag-positive reservoir cells can be identified by a new technique and can be cleared by CTL ? Una O’Doherty June 29, 2013.
Controversies in HIV Cure Research Debate 1. Is there ongoing replication under HAART? Mario Stevenson and Frank Maldarelli Moderator: Steve Deeks.
Over 50 million HIV/AIDS cases have occurred worldwide Over 40 million people are currently living with HIV/AIDS 95% of all cases are in developing countries.
Alternative RNA splicing in latently infected T cells generates chimeric cellular:HIV mRNAs with the potential to generate Tat and reactivate infection.
EARLY ANTIRETROVIRAL TREATMENT HIV Cure Research Training Curriculum (CUREiculum) Early Antiretroviral (ART) Treatment Module by: Scientific Leads: Dr.
2014 “Towards an HIV Cure” symposium Melbourne A novel assay that precisely measures the size of the latent HIV reservoir reveals that ART-nai ̈ ve individuals.
Measuring the latent HIV Reservoir
David M. Margolis, MD Professor of Medicine Towards an HIV cure: medical, social and ethical challenges in research and testing.
2014 “Towards an HIV Cure” symposium Melbourne The Immune Checkpoints PD-1, LAG-3 and TIGIT are Biomarkers of HIV Infected Cells During ART and Identify.
HIV Structure, Lifecycle, and Replication
Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.
HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial James Williams 1,2,3, Jacob Hurst 1,2,3,
The role of PI3K signaling pathways in HIV-1 infection of resting CD4+T-cells Suha Saleh, Paul Cameron, Georgina Sallmann, Anthony Jaworowski, and Sharon.
Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy S. Fourati 1, R. Calin 2, G. Carcelain 3, P.
Immune correlates of unusual control of viral replication after cessation of HAART Ellen Van Gulck 1, Leo Heyndrickx 1, Céline Merlin 1, Sandra Coppens.
AIDS supplement. History of HIV Originated in Africa in the late 1950’s Originally found in nonhuman primates and may have mutated First documented in.
Long-term ART initiated during primary HIV-1 infection limits the HIV-1 reservoir size but not to levels found in LTNPs Eva Malatinkova, Ward De Spiegelaere,
HIV Cellular Pathogenesis III
Evaluation of residual HIV-1 replication among individuals receiving different antiretroviral treatment regimens Giron, LB; Tenore, S; Gabriel, R; Janini,
DIAGNOSIS OF HIV INFECTION THE LABORATORY BY DR. K.BUJJIBABU.MD.
Stability of HCV, HIV-1 and HBV nucleic acids in plasma samples stored at different temperatures Marta José, Rodrigo Gajardo and Juan I. Jorquera Instituto.
Characterization of persistent HIV-1 in a broad spectrum of CD4 + T-cells isolated from peripheral blood, bone marrow, lymphoid tissue and gut associated.
Viral Tissue Reservoirs Are Determined Early and Little Viral RNA Is Detected during Suppression in the Macaque Model Zandrea Ambrose, Ph.D. Division of.
A murine viral outgrowth assay to detect residual HIV-1 in patients with undetectable viral loads Kelly A. Metcalf Pate, DVM, PhD, DACLAM Joel N. Blankson,
Measuring the HIV reservoirs: new and improved methods Sarah Palmer Westmead Millennium Institute for Medical Research University of Sydney.
Yerkes National Primate Research Center
Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.
Persistent HIV-1 infection in duodenal mucosa and memory CD8+ T cell differentiation Liliana Belmonte 1 PhD; Alberto Zalar 2 MD; Patricia Baré 1 PhD; Noel.
The Use of Pooled Viral Load Testing to Identify Antiretroviral Treatment Failure Davey Smith 1, Susanne May 2, Josué Perez-Santiago 1, Matthew Strain.
LOWERING THE DETECTION LIMITS OF HIV-1 VIRAL LOAD USING REAL-TIME IMMUNO-PCR FOR HIV-1 P24 ANTIGEN Niel T. Constantine, Ph.D., Daniel Edelman, M.S., Janet.
HIV Cellular Pathogenesis III Benhur Lee, M.D.. Adult v. infant (IgG v. IgA) CTL response (MHC tetramers) p24 antigenimia Ab response Viral load.
HIV rebound and meningoencephalitis following ART interruption after allogeneic hematopoietic stem cell transplant: an investigation of the source of HIV.
Sporadic excesses of unintegrated HIV DNA can occur in HIV+ patients on HAART Una O’Doherty University of Pennsylvania.
Lessons Learned from Transient Remission Cases: Clues to Biomarkers of HIV Rebound Katherine Luzuriaga, MD University of Massachusetts.
Chelsea Harmon Catherine Hanson Abby Llaneza Jen Williams
ImmunoPathogenesis of HIV Disease Overview of HIV Epidemic Basic biology of HIV-1 Stages of HIV Disease Viral and Cellular Dynamics after HAART HIV Therapy.
Infection and Disease Fungi Parasites Nosocomial infection Diagnosis of infectious disease.
IAS Members Meeting July 19th 2011 Achievements and learning over the past 30 years: what do we need next? Françoise BARRÉ-SINOUSSI Regulation of Retroviral.
HIV: Science, Sex and Society. Lecture 1. Mechanisms of viral persistence in the face of antiviral therapy. Mario Stevenson, Ph.D Department of Medicine.
The Future of HIV/AIDS: The Road to a Cure. How HIV persists during therapy?  Ongoing viral replication occurs in subjects on suppressive HAART (TW Chun,
Robert F. Siliciano, MD, PhD Professor of Medicine The Johns Hopkins University School of Medicine Baltimore, Maryland Update on HIV Cure Research FORMATTED:
T-cell activation positively correlates with cell-associated HIV-DNA level in PBMCs in viremic patients with acute or chronic HIV-1 infection Laurence.
Basics of Human Immunodeficiency Virus (HIV) Brian Rybarczyk, PhD University of North Carolina- Chapel Hill.
Immune reconstitution Anjie Zhen, PhD
The HIV virus. Objectives At the end of this session the participants will be able to: 1. Understand basic HIV structure 2. Describe the significance.
Source: A DULTS AND C HILDREN L IVING WITH HIV/AIDS (Est. Dec 2007) deaths: 2,900,000 in ,100,000 in 2007 new cases: 2,500,000 in.
Cellular immune control of Human Immunodeficiency Virus (HIV) Dr. Ali Jalil Ali College of pharmacy.
IMMUNODEFICIENCIES HIV2 324 PHT Dr. Sarah I. Bukhari PhD in Clinical Microbiology Department of Pharmaceutics Office: rd floor
Alexander Pasternak Laboratory of Experimental Virology, Department of Medical Microbiology Academic Medical Center of the University of Amsterdam Amsterdam,
The impact of treatment duration on defective and expanded identical HIV genomes in T cell subsets from peripheral blood and tissues Eunok Lee.
Prolonged HIV-1 Remission and Viral Rebound in an Individual Treated During Hyperacute Infection Timothy Henrich, Hiroyu Hatano, Alison Hill, Oliver Bacon,
Retrovirus.
HIV Cure: Current Status and Future Perspectives
Conflict of Interest No conflicts of interest to declare.
Feedback meeting September 2017
Volume 2, Issue 8, Pages (August 2015)
HEATHER Feedback Meeting
Immunodeficiency (2 of 2)
AIM: How does HIV cause someone to get sick?
Immunodeficiency (2 of 2)
Volume 21, Issue 3, Pages (October 2017)
Steven Yukl UCSF and San Francisco VA
Presentation transcript:

Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Sulggi Lee, M.D., Ph.D. Assistant Professor of Medicine University of California, San Francisco July 20, 2015

Chronic/Latent Viral Infections Lead to Prolonged Antibody Responses VZV Antibody Half-Life ~ 50 Years Amanna NEJM 2007

Time on HAART (years) Latently Infected Cells (Infectious Units per 10 6 cells) The Size of the HIV Reservoir is Also Stable During Long-Term ART Time to eradication > 73.4 years Siliciano Nat Med 2003

Anti-HIV Antibody Levels May Distinguish Individuals With Different HIV Reservoir Sizes Burbelo JID 2014 Antibody Levels Light Units (LU) Anti-gp41 Levels * * * *

Anti-HIV Antibody Levels May Be Sensitive Measures of the Reservoir Size Over Time Longitudinal data from Burbelo JID 2014 Anti –gp41 Levels Median Years of ART Antibody Levels Light Units (LU) Pre-ART 0

Hypothesis: Antibody Levels in Blood at Steady-State Reflect Total Body Reservoir Size Y Y Y Y Y Y Y Y Y Y Y Y Y CD4+ Primary Infection Establishment of Infection in Lymphoid Tissue Antibody Production

Current Issues in Measuring HIV Reservoir How to measure the success of HIV cure treatments if no scalable, precise assay of the reservoir? The HIV reservoir is much larger in tissue than in blood – A reliable measure that reflects the HIV reservoir in tissue? Most measures of the HIV reservoir are virologic assays, not cell-based assays measuring host response to virus Eriksson PLoS Pathogens 2013, Ho Cell 2013, Chun JID 2008, Yukl JID 2010

Study Design Aim: Determine whether anti-HIV antibody levels reflect the size of the latent reservoir Participants: 61 HIV+ individuals who – Initiated ART during chronic infection – Have been ART-suppressed for at least 3 years

P I V Q N I Q G Q M V H Q A I S P R T L N A W V K V V E E K A F S P E V I P M F S A L S E G A T P Q D L N T M L N T V G G H Q A A M Q M L K E T I N E E A A E W D R V H P V H A G P I A P G Q M R E P R G S D I A G T T S T L Q E Q I G W M T N N P P I P V G E I Y K R W I I L G L N K I V R M Y S P T S I L D I R Q G P K E P F R D Y V D R F Y K T L R A E Q A S Q E V K N W M T E T L L V Q N A N P D C K T I L K A L G P A A T L E E M M T A C Q G V G G P G H K A R V L * Luciferase One letter code for amino acids Y Y Y Y Y Y Y C C C C L L L L = linear epitope C= conformational epitopes Novel Luciferase Immunoprecipitation Systems (LIPS) Assay Detects Conformational Antibodies

Question: Are HIV Reservoir Measures Associated with Anti-HIV Antibody Levels? gp120 gp41 reverse transcriptase integrase protease matrix p24 12 Measures of the HIV Reservoir 7 Anti-HIV Antibody Levels Erikkson PLoS Pathogens 2013, Lewin J Virol 1999, Burbelo JID 2014 Permutation Testing To test the association between reservoir and antibody measures, adjusted for multiple comparisons Total HIV DNA CD4+ T cells (rtPCR) PBMCs (ddPCR) Resting CD4+ T cells (ddPCR) Integrated HIV DNA CD4+ T cells (rtPCR) PBMCs (aluPCR) Resting CD4+ T cells (aluPCR) 2-LTR HIV DNA CD4+ T cells (rtPCR) PBMCs (ddPCR) Resting CD4+ T cells (ddPCR) Unspliced HIV RNA CD4+ T cells (rtPCR) Plasma HIV RNA Plasma (rtPCR single copy assay) Infectious Units per Million Resting CD4+ T cells (VOA)

Study Participant Characteristics *Number (%) Median and Interquartile Range shown

Measures of the HIV DNA (Total, Integrated) are Correlated with Anti-HIV Antibody Levels gp120gp41RTINTPRMAp24 Total HIV DNA CD4+ T cells (rtPCR) PBMCs (ddPCR) Resting CD4+ T cells (ddPCR) Integrated HIV DNA CD4+ T cells (rtPCR) PBMCs (aluPCR) Resting CD4+ T cells (aluPCR)

Measures of the “Active” or Replication-Competent Reservoir are Weakly Correlated with Anti-gp120 Levels gp120gp41RTINTPRMAp24 2-LTR HIV DNA CD4+ T cells (rtPCR) PBMCs (ddPCR) Resting CD4+ T cells (ddPCR) Unspliced HIV RNA CD4+ T cells (rtPCR) Plasma HIV RNA Plasma (rtPCR SCA) Infectious Units (Per 10 6 ) Resting CD4+ T cells (VOA)

Overall, HIV Reservoir Measures Strongly Correlate with Anti-gp120, -gp41, and -RT Levels gp120gp41RTINTPRMAp24 All HIV Reservoir Measures Correlation (R) P * Adjustment for age, nadir CD4+ T cell count, proximal CD4+ T cell count, years of ART suppression, pre-ART viral load did not significantly alter these results.

Conclusions We observed a strong association between measures of the latent HIV reservoir and anti-HIV antibody levels Overall, anti-gp120, -gp41, and -RT were most strongly correlated with HIV reservoir size Total and integrated HIV DNA were strongly associated with antibody levels against Env and Pol proteins Measures of the “active” (CA-US RNA, 2-LTR DNA) and replication-competent (VOA) reservoir were weakly associated with anti-gp120 levels

Remaining Questions Can viral RNA or proteins be produced in cells with defective proviruses? – And elicit a host immune response? Is there preferential B cell response? – Relative “importance” of Env > Pol > Gag antigens? Why are HIV CA-DNA and CA-RNA but not plasma RNA correlated with anti-HIV antibody levels? – Do antibody levels do a good job of quantifying the HIV tissue reservoir?

Can Anti-HIV Antibody Levels Monitor Response to HIV Cure Strategies? Antibody Levels Pre-TreatmentAntibody Levels Post-Treatment

Acknowledgements UCSF – Steven Deeks – Saunak Sen NIH/NIDCR – Peter Burbelo Johns Hopkins – Robert Siliciano – Janet Siliciano University of Melbourne – Sharon Lewin UCSD – Douglas Richman – Matthew Strain University of Pennsylvania – Una O’Doherty University of Sydney – Sarah Palmer University of Montreal – Nicolas Chomont – Remi Fromentin